Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:EW
CUSIP28176E10
Phone949-250-2500
Debt
Debt-to-Equity Ratio0.19
Current Ratio1.86
Quick Ratio1.47
Price-To-Earnings
Trailing P/E Ratio36.78
Forward P/E Ratio29.99
P/E Growth2.01
Sales & Book Value
Annual Sales$3.44 billion
Price / Sales8.52
Cash Flow$4.3139 per share
Price / Cash32.40
Book Value$13.97 per share
Price / Book10.01
Profitability
EPS (Most Recent Fiscal Year)$3.80
Net Income$583.60 million
Net Margins19.59%
Return on Equity29.11%
Return on Assets16.07%
Miscellaneous
Employees12,200
Outstanding Shares209,390,000
Market Cap$28.91 billion
Edwards Lifesciences (NYSE:EW) Frequently Asked Questions
What is Edwards Lifesciences' stock symbol?
Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."
When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work?
Edwards Lifesciences's stock split before market open on Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were distributed to shareholders after the market closes on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.
How will Edwards Lifesciences' stock buyback program work?
Edwards Lifesciences declared that its board has initiated a stock repurchase plan on Thursday, December 7th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its stock is undervalued.
How were Edwards Lifesciences' earnings last quarter?
Edwards Lifesciences Corp (NYSE:EW) announced its quarterly earnings data on Thursday, July, 26th. The medical research company reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.13 by $0.11. The medical research company had revenue of $972 million for the quarter, compared to the consensus estimate of $968.32 million. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The firm's revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.08 EPS. View Edwards Lifesciences' Earnings History.
When is Edwards Lifesciences' next earnings date?
What guidance has Edwards Lifesciences issued on next quarter's earnings?
Edwards Lifesciences issued an update on its FY18 earnings guidance on Thursday, July, 26th. The company provided EPS guidance of $4.60-4.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.63. The company issued revenue guidance of high end of $3.5-3.9 billion, compared to the consensus revenue estimate of $3.84 billion.Edwards Lifesciences also updated its Q3 guidance to $0.93-1.03 EPS.
What price target have analysts set for EW?
20 analysts have issued 1-year price objectives for Edwards Lifesciences' stock. Their forecasts range from $115.00 to $174.00. On average, they anticipate Edwards Lifesciences' share price to reach $151.7895 in the next year. This suggests a possible upside of 8.6% from the stock's current price. View Analyst Price Targets for Edwards Lifesciences.
What is the consensus analysts' recommendation for Edwards Lifesciences?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences.
What are Wall Street analysts saying about Edwards Lifesciences stock?
Here are some recent quotes from research analysts about Edwards Lifesciences stock:
- 1. Northland Securities analysts commented, "We doubt the latter is true. At the same time, how much of the outlook is predicated on a successful launch of these new platforms? We have been sounding the alarm on Edwards’ TMVR program for over a year. Our checks in Europe, on both CardiAQ and SAPIEN M3 have been poor. Edwards did not provide any real update on these programs on the Q2-18 call. At the same tie, both Medtronic and Abbott have started their pivotal trials, and it is unclear to us if figuring out a transseptal route is the only thing delaying the TMVR program. Our checks in Europe suggest that there is more to this than meets the eye." (7/27/2018)
- 2. According to Zacks Investment Research, "Over the past six months, Edwards Lifesciences has outperformed its industry. We are upbeat about the company witnessing strong transcatheter valve sales in the domestic market as well as overseas. Edwards Lifesciences’ raised 2018 EPS guidance buoys optimism. We are also upbeat about the receipt of CE Mark for its self-expanding CENTERA valve. The FDA approval of De Novo request for the Acumen Hypotension Prediction Index (HPI) software is also encouraging. Management expects to gain traction in the ever-expanding TAVR market based on increasing preference for transcatheter aortic valve replacement as well as compelling clinical evidence, leading to strong adoption of THV therapy. However, tough competitions in the cardiac devices market and reimbursement issues continue to pose challenges." (7/16/2018)
Who are some of Edwards Lifesciences' key competitors?
Some companies that are related to Edwards Lifesciences include Intuitive Surgical (ISRG), Align Technology (ALGN), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), WILLIAM DEMANT/ADR (WILYY), Steris (STE), Inogen (INGN), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Halyard Health (HYH), CONSORT Med PLC/S (CSRMY), Sientra (SIEN) and Invacare (IVC).
Who are Edwards Lifesciences' key executives?
Edwards Lifesciences' management team includes the folowing people:
- Mr. Michael A. Mussallem, Chairman & CEO (Age 65)
- Mr. Scott B. Ullem, Corp. VP & CFO (Age 51)
- Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 56)
- Mr. Larry L. Wood, Corp. VP of Transcatheter Heart Valve (Age 52)
- Ms. Catherine M. Szyman, Corp. VP of Critical Care (Age 51)
Has Edwards Lifesciences been receiving favorable news coverage?
News headlines about EW stock have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Edwards Lifesciences earned a media and rumor sentiment score of 0.02 on Accern's scale. They also gave media stories about the medical research company an impact score of 46.12 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Edwards Lifesciences.
Who are Edwards Lifesciences' major shareholders?
Edwards Lifesciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.40%), Bank of New York Mellon Corp (3.57%), FMR LLC (3.21%), Brown Advisory Inc. (1.85%), American Century Companies Inc. (1.16%) and Bank of America Corp DE (1.15%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.
Which major investors are selling Edwards Lifesciences stock?
EW stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bank of New York Mellon Corp, Montag & Caldwell LLC, American Century Companies Inc., Winslow Capital Management LLC, Factory Mutual Insurance Co., NN Investment Partners Holdings N.V. and BlackRock Inc.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.
Which major investors are buying Edwards Lifesciences stock?
EW stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, First Trust Advisors LP, Voya Investment Management LLC, Jennison Associates LLC, AKO Capital LLP, First Republic Investment Management Inc. and Brown Advisory Inc.. Company insiders that have bought Edwards Lifesciences stock in the last two years include Catherine M Szyman, Dylan Sidoo and Kieran Gallahue. View Insider Buying and Selling for Edwards Lifesciences.
How do I buy shares of Edwards Lifesciences?
Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Edwards Lifesciences' stock price today?
One share of EW stock can currently be purchased for approximately $139.77.
How big of a company is Edwards Lifesciences?
Edwards Lifesciences has a market capitalization of $28.91 billion and generates $3.44 billion in revenue each year. The medical research company earns $583.60 million in net income (profit) each year or $3.80 on an earnings per share basis. Edwards Lifesciences employs 12,200 workers across the globe.
How can I contact Edwards Lifesciences?
Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]
MarketBeat Community Rating for Edwards Lifesciences (NYSE EW)
MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe EW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EW will underperform the S&P 500 over the long term. You may vote once every thirty days.
